• Most Popular
  • Most Shared

UPDATE 1-SciClone says hepatitis C drug trial shows promise

Mon Feb 11, 2008 9:28am EST

Stocks

   

(Adds details, share movement)

Feb 11 (Reuters) - SciClone Pharmaceuticals Inc (SCLN.O) and Sigma-Tau S.p.A said interim data from a late-stage trial of hepatitis C drug, Zadaxin, was promising, with 171 out of 553 total patients having no detectable hepatitis C virus in the blood at the end of 48 weeks of therapy.

Total patients included both the treatment group, that received the drug being investigated, and the control group, which received a dummy drug, the company said, adding the breakdown between the two groups was not known.

Full data from the trial will be available in the third quarter of 2008, the companies said in a joint statement.

The drug is being evaluated in combination with the current standard therapies for the liver-destroying hepatitis C virus.

Shares of SciClone were trading at $2.03 before the bell. The stock had closed at $1.98 Friday on the Nasdaq. (Reporting by Varsha Tickoo in Bangalore; Editing by Deepak Kannan)



More from Reuters

A Greenpeace activist dressed as one of the "Four Horsemen of the Apocalypse" rides outside the parliament building during a brief protest in Copenhagen December 13, 2009. REUTERS/Christian Charisius

The face of climate protest

Protesters around the globe called for an end to global warming as climate talks in Copenhagen entered their sixth day.  Video 

    Climate conference
    In this photo reviewed by the U.S. Military, a guard leans on a fencepost as a Guantanamo detainee (L) jogs inside the exercise yard at Camp 5 detention center, at the U.S. Naval Base in Guantanamo Bay, January 21, 2009. REUTERS/Brennan Linsley/Pool

    Life after Guantanamo

    Critics are worried that Gitmo prisoners once dubbed "enemy combatants" will be using prisons as pulpits for anti-American rhetoric once they're moved to U.S. soil.  Full Article 

    U.S.
    Lockheed Martin Chief Executive Robert Stevens answers a question during the Reuters Aerospace and Defense Summit in Washington December 14, 2009. REUTERS/Molly Riley

    Lockheed eyes deals

    The future demands of cybersecurity make that sector one of many the aerospace giant sees as an acquisition target in the coming year.  Full Article 

    Aerospace and Defense Summit